Department of Medicine, University of Udine, 33100, Udine, Italy.
Department of Translational and Precision Medicine, "Sapienza" University of Rome, 00161, Rome, Italy.
Endocrine. 2021 Sep;73(3):648-657. doi: 10.1007/s12020-021-02705-1. Epub 2021 Apr 5.
Understanding the molecular mechanisms underlying papillary thyroid cancer (PTC) proved to be vital not only for diagnostic purposes but also for tailored treatments. Despite the strong evidence of heritability, only a small subset of alterations has been implicated in PTC pathogenesis. To this reason, we used targeted next-generation sequencing (NGS) to identify candidate variants implicated in PTC pathogenesis, progression, and invasiveness.
A total of 42 primary PTC tissues were investigated using a targeted next-generation sequencing (NGS) panel enlisting 47 genes involved in DNA repair and tumor progression.
We identified 57 point mutations in 78.5% of samples (n = 32). Thirty-two somatic mutations were identified exclusively in known thyroid cancer genes (BRAF, KRAS, NRAS, and TERT). Unpredictably, 45% of the all identified mutations (n = 25) resulted to be germline, most affecting DNA repair genes. Interestingly, none of the latter variants was in the main population databases. Following ACMG classification, 20% of pathogenic/likely pathogenic and 68% of variant of unknown significance were identified.
Overall, our results support the hypothesis that rare germline variants in DNA repair genes are accountable for PTC susceptibility. More data, including the segregation analysis in affected families, should be collected before definitely annotate these alterations and to establish their potential prognostic and treatment implications.
了解甲状腺乳头状癌 (PTC) 的分子机制不仅对诊断很重要,对靶向治疗也很重要。尽管有很强的遗传证据,但只有一小部分改变与 PTC 的发病机制有关。出于这个原因,我们使用靶向下一代测序 (NGS) 来鉴定与 PTC 发病机制、进展和侵袭性相关的候选变体。
我们使用了一个靶向下一代测序 (NGS) 面板对 42 个原发性 PTC 组织进行了调查,该面板列出了涉及 DNA 修复和肿瘤进展的 47 个基因。
我们在 78.5%的样本(n=32)中发现了 57 个点突变。32 个体细胞突变仅在已知的甲状腺癌基因(BRAF、KRAS、NRAS 和 TERT)中被发现。出乎意料的是,所有鉴定出的突变(n=25)中有 45%是种系突变,大多数影响 DNA 修复基因。有趣的是,后者的变体没有一个在主要的人群数据库中。根据 ACMG 分类,鉴定出 20%的致病性/可能致病性和 68%的意义不明的变异。
总的来说,我们的结果支持这样的假设,即 DNA 修复基因中的罕见种系变异是 PTC 易感性的原因。应该收集更多的数据,包括在受影响的家庭中的分离分析,然后才能确定这些改变,并确定它们的潜在预后和治疗意义。